Understanding how prostate cancer responds to B7-H3 targeted treatments
Official title: Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)
Funded at University of Minnesota · NIH-11061222 · Data updated 2026-11-12
This study is looking at why some men with prostate cancer, who haven't responded to regular treatments, might benefit from new therapies that target a protein called B7-H3, using advanced techniques to understand how their cancer cells behave.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $322,102 |
| NIH project number | 5R37CA288972-02 |
| Project ID | NIH-11061222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are prostate cancer patients who have shown resistance to androgen receptor-targeting therapies.
✕Less likely to help
Patients with early-stage prostate cancer who have not undergone androgen receptor-targeting treatments may not benefit from this research.
What this research studies
This research investigates the mechanisms behind the sensitivity of prostate cancer to therapies that target the B7-H3 protein. It focuses on patients who have developed resistance to standard androgen receptor-targeting treatments. By examining the role of specific transcription factors and regulatory sites that influence B7-H3 expression, the study aims to uncover why some patients benefit from B7-H3 therapies. The research employs advanced techniques like single-cell RNA sequencing to analyze tumor cells and their responses to treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for prostate cancer patients who have become resistant to current therapies.
How similar studies have gone: Previous studies have shown promising results with B7-H3 targeted therapies in prostate cancer, indicating potential for success in this research.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Hwang, Justin H. — University of Minnesota
- Study coordinator: Hwang, Justin H.
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.